Neoadjuvant chemotherapy for primary adenocarcinomas of the urinary bladder: a single-site experience

Bin Yu1,2†, Jin Zhou3†, Hongzhou Cai1†, Ting Xu1, Zicheng Xu1,2, Qing Zou1* and Min Gu2*

Abstract

Background: Adenocarcinoma of the urinary bladder is a rare malignancy. Radical surgery is suggested as the best available treatment for early-stage disease, but there is currently no consensus on standard chemotherapy regimen for advanced stage. We assessed the feasibility and effect of neoadjuvant chemotherapy with gemcitabine and cisplatin (GC) plus S-1 for patients with locally advanced primary adenocarcinomas of the urinary bladder.

Methods: Six patients with locally advanced urachal or non-urachal (n = 3, each) primary adenocarcinoma of the bladder were treated from October 2010 to October 2013 at a single center. All the patients were treated with 3 cycles (21d, each) of GC plus S-1 (gemcitabine, 1000 mg/m², days 1 and 8; cisplatin, 70 mg/m², day 2; and S-1, 50 mg bid, day 1-14). After neoadjuvant chemotherapy, patients with urachal cancer were treated with en bloc radical cystectomy and umbilicectomy; the remaining 3 patients were treated with cystectomy.

Results: All patients successfully completed the neoadjuvant chemotherapy without serious side effects. Two patients were assessed as complete response, 2 as partial response, 1 as stable disease and 1 as progressive disease.

Conclusions: Despite the limitations of a small study population, the GC plus S-1 regimen for locally advanced primary adenocarcinoma of the urinary bladder was effective, and facilitated the success of surgery to a certain extent. Short follow-up time was also a limitation of our study. More studies are needed to evaluate the results.

Keywords: Neoadjuvant chemotherapy, Primary adenocarcinomas of bladder, Survival

Background

Primary adenocarcinomas of the bladder account for less than 2% of primary bladder cancers, and are rarely encountered [1,2]. Primary adenocarcinomas of the urinary bladder can be subdivided into urachal and non-urachal adenocarcinoma. Radical surgery is considered the best available treatment, but the 5-year survival rates (11%-61%) have not been satisfactory [3]. Patients with urachal adenocarcinoma often present with higher stage disease because the disease arises out-side of the bladder and causes fewer symptoms before its invasion of surrounding organs. For patients with locally advanced primary adenocarcinomas of the bladder, neoadjuvant chemotherapy can be a good option: it helps downstage the cancer before radical surgery, eradicates potential micrometastases, and may avoid local and distant failure [4,5]. However, primary adenocarcinomas of the urinary bladder are so rare that experience of chemotherapy is limited [6]. The National Comprehensive Cancer Network (NCCN; version 2.2014) suggests that chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) is not effective for primary adenocarcinomas of the urinary bladder, and according to some reports a 5-fluorouracil (5-FU)-based regimen should be tried [6,7]. Furthermore, gemcitabine plus cisplatin (GC) has proved viable as first-line chemotherapy for urothelial (transitional) cell carcinoma with overall survival comparable to that of MVAC but with fewer side effects [8]. Herein, we report our experience in treating 6 cases of
locally advanced primary adenocarcinomas of the bladder, 3 urachal and 3 non-urachal.

Methods
This prospective observational study was approved by the Institutional Review Board of Nanjing Medical University, Nanjing, China. Each patient provided written informed consent before treatment. Six patients with pathologically diagnosed locally advanced primary adenocarcinoma of the bladder were treated between October 2010 and October 2013 at Affiliated Cancer Hospital of Jiangsu Province of Nanjing Medical University. The patients’ demographics and clinical data were collected. All the pathology gained through biopsy via cystoscopy was confirmed as adenocarcinoma before chemotherapy. Computed tomography of cranial, chest and abdomen was done to exclude the metastatic adenocarcinoma. All patients were confirmed primary adenocarcinoma of the bladder at a locally advanced stage, with clinical stage $\geq T_2$, without distant metastasis, and with or without lymph node metastasis. All the patients were treated with GC plus S-1 chemotherapy for 3 cycles, 21 d/cycle: gemcitabine, 1000 mg/m$^2$, days 1 and 8; cisplatin, 70 mg/m$^2$, day 2; and S-1, 50 mg bid, days 1-14. The adenocarcinomas were classified as urachal or non-urachal prior to surgery. Tumors were considered urachal if the tumor was located at the dome of the bladder rather than the anterior bladder wall, with the most critical features being the presence of a sharp demarcation between the tumor and the surface epithelium, and the exclusion of a primary adenocarcinoma elsewhere. Patients with urachal bladder cancer were treated with en bloc radical cystectomy and umbilectomy. Non-urachal patients were treated with cystectomy after neoadjuvant chemotherapy. The response of the target lesions to treatment was evaluated by computed tomography scan, in accordance with the Response Evaluation Criteria In Solid Tumors (RECIST 1.1) guidelines: complete response (disappearance of target lesion); partial response ($\geq 30\%$ decrease in the sum of the longest diameter of the target lesion, from baseline); stable disease (between a partial response and progressive disease); and progressive disease ($\geq 20\%$ increase in the sum of the longest diameter of the target lesion, from nadir) [9]. The patients were followed, beginning at diagnosis.

Results
Six patients were enrolled in this study: 5 men and 1 woman, aged 49 to 79 years (mean 62.5 y; Table 1). Hematuria and lower abdominal pain were the most frequently reported symptoms at presentation. Specifically, 4 patients presented with hematuria and 3 with lower abdominal pain (1 patient with both symptoms). One, 3, and 2 patients were in stages $T_2$, $T_3$, and $T_4$, respectively. One month after the 3 cycles of neoadjuvant chemotherapy, 2, 2, 1, and 1 patient were evaluated as complete response, partial remission, stable disease, and progressive disease, respectively. No patient stopped chemotherapy because of side effects. Three patients were judged to have non-urachal adenocarcinoma. Two of these received en bloc radical cystectomy and umbilectomy. One patient refused surgery. The 3 patients with non-urachal adenocarcinoma were treated by cystectomy. After surgery, pathology confirmed pure primary adenocarcinoma in 5 patients.

Four patients experienced grade 2 myelosuppression. Three patients had transient elevated serum creatinine (averaging 1.5-fold normal). Three patients had nausea, vomiting, and loss of appetite. All the patients recovered from the side effects after completion of chemotherapy.

Discussion
Adenocarcinoma of the urinary bladder is a rare malignancy with a poor prognosis. Patient survival is similar to that of muscle-invasive urothelial carcinoma [10]. Unlike other cancers, there is currently no consensus regarding a standard chemotherapy regime for adenocarcinoma of the urinary bladder. In the present study, we used GC plus S-1 for neoadjuvant chemotherapy. Johnson et al. [11] reported that adenocarcinomas of the urinary bladder have a clinical behavior similar to that of urothelial (transitional) cell carcinoma of the bladder, and GC as first-line chemotherapy for urothelial cell carcinoma has fewer side effects and similar overall survival compared with MVAC. 5-FU is widely used in the treatment of adenocarcinomas (such as

Table 1 Case summaries of 6 patients with primary adenocarcinomas of the urinary bladder

| Patient | Age  | Gender | Symptom      | Tumor | Stage | Response | PFS, mo | Survival, mo |
|---------|------|--------|--------------|-------|-------|----------|--------|-------------|
| 1       | 71   | Male   | Pain         | Non-urachal | T3b   | Complete | 3      | 7           |
| 2       | 68   | Male   | Hematuria    | Non-urachal | T2b   | Partial  | >18    | 18$^c$      |
| 3       | 79   | Female | Hematuria    | Non-urachal | T4b   | Stable disease | 6     | 12          |
| 4       | 67   | Male   | Pain         | Urachal | T3b   | Complete | >20    | 20$^c$      |
| 5       | 51   | Male   | Hematuria    | Urachal | T3b   | Partial  | >10    | 10$^c$      |
| 6       | 49   | Male   | Pain and hematuria | Urachal | T4a   | Progressive disease | >6     | 6$^c$       |

$^a$After neoadjuvant chemotherapy; $^b$progression-free survival; $^c$still alive.
stomach cancer), and Logothetis et al. [6] reported using 5-FU to treat urachal cancers, but continuous 5-FU infusion has recently been replaced by S-1, to avoid some of the inconveniences and adverse effects of 5-FU [12,13]. S-1 is a novel oral Xylopyrimidine derivative that consists of tegafur, 5-chloro-2, 4-dihydropyrimidine (CDHP), and potassium oxonate.

All the 6 patients of the present study received GC plus S-1 for 3 cycles, and no patient failed to complete the cycles because of side effects. The most severe side effect was grade 2 myelosuppression such as leucopenia and thrombocytopenia. This was resolved within 2 to7 days after symptomatic treatment with granulopoietin. More severe side effects can be treated by blood transfusion. No patient suffered renal function impairment because of chemotherapy. Three patients experienced transient elevated serum creatinine (averaging 1.5-fold normal). However, this also returned to normal after the end of treatment. Thus, the safety of this chemotherapy regime was acceptable.

In the present study, we applied GC plus S-1. Two patients had a partial response, and 2, 1, and 1 patient had complete response, stable disease, and progressive disease, respectively. In contrast, a study conducted by the MD Anderson Cancer Center (MDACC) used combinations of 5-FU and cisplatin and reported a 33% response rate [7]. Thus, our results are encouraging. Several factors may contribute to the difference in response rate. Firstly, the composition of patients is different. The patients in MDACC report are pure with urachal cancers, while in our study, NU adenocarcinoma patients are included. Secondly, the differences in the predominant ethnicities of the study populations (Houston, TX cf. Nanjing, China) may have influenced the response rate to chemotherapy. Many studies report that genetic polymorphisms exist in different races, especially in drug-metabolizing enzymes, drug targets, and drug receptors [14,15]. These genetic polymorphisms may have contribution to the response rate. Compared with western populations, the patients in China have more attention from their family. Better food and family care may encourage the nutrients and psychological healthy of patients. More importantly, adenocarcinomas of the urinary bladder are rare and all studies are limited in the small cases. The choice of chemotherapy regimens has recently been replaced by S-1, to avoid some of the inconveniences and adverse effects of 5-FU [12,13]. The shorter follow-up time, small case number, and the heterogeneity of patient 1 (who refused surgery and even other treatments) handicapped our analysis in this study. However, our results are enough to warrant further clinical studies with a larger number of patients with primary adenocarcinomas of the urinary bladder, to evaluate the efficacy of GC plus S-1 combination chemotherapy for neoadjuvant chemotherapy, and even for adjuvant chemotherapy.

Despite the limitations, the preliminary results of this study show that chemotherapy with GC plus S-1 for primary adenocarcinomas of the urinary bladder is effective. For patients at a locally advanced stage, this regimen effectively downstaged the tumor and may eradicate potential micrometastases, without increasing the difficulty of surgery.

Conclusions

Chemotherapy with the GC plus S-1 regimen for patients with primary adenocarcinomas of the urinary bladder is effective. To a certain extent, neoadjuvant chemotherapy facilitates surgery of patients at the locally advanced stage. Our treatments should be investigated in a randomized controlled trial to confirm these outcomes.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

QZ and MG contributed substantially to the conception and design. BY and HC helped to acquire the data and draft the manuscript. QZ, TX and ZX performed statistical analyses. JZ contributed to language editing. All authors read and approved the final manuscript.

Acknowledgments

We are grateful to Professor Changjun Yin (First Affiliated Hospital of Nanjing Medical University), and are thankful for the funding support (ZQ 201302) we received from the Affiliated Cancer Hospital of Jiangsu Province of Nanjing Medical University, Nanjing, China.

Author details

1Department of Urologic Surgery, Affiliated Cancer Hospital of Jiangsu Province of Nanjing Medical University, Nanjing, China. 2Department of Urology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

Received: 4 May 2014 Accepted: 22 January 2015
Published: 28 January 2015

References

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.
2. Abol-Enein H, Kava BR, Carmack AJ. Nonurothelial cancer of the bladder. Urology. 2007;69(1 Suppl):93–104.
3. Dahm F, Gschwend JE. Malignant non-urothelial neoplasms of the urinary bladder: a review. Eur Urol. 2003;44(6):872–81.
4. Calabro F, Sternberg CN. Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer. Eur Urol. 2009;55(2):348–58.
5. Clark PE. Neoadjuvant versus adjuvant chemotherapy for muscle-invasive bladder cancer. Expert Rev Anticancer Ther. 2009;9(6):821–30.
6. Logothetis CJ, Samuels M, Ogden S. Chemotherapy for adenocarcinomas of bladder and urachal origin: 5-fluorouracil, doxorubicin, and mitomycin-C. Urology. 1985;26(3):252–5.
7. Siefer-Radkte AO, Gee J, Shen Y, Wen S, Daliani D, Millikan RE, et al. Multimodality management of urachal carcinoma: the M. D. Anderson Cancer Center experience. J Urol. 2003;169(4):1295–8.
8. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18(17):3068–77.
9. Sohaib AR. RECIST rules. Cancer Imaging. 2012;12:345–6.
10. Ploeg M, Aben KK, de Hulsbergen-van Kaa CA, Schoenberg MP, Witjes JA, Kiemeneij LA. Clinical epidemiology of nonurothelial bladder cancer: analysis of the Netherlands Cancer Registry. J Urol. 2010;183(3):915–20.
11. Johnson OE, Hogan JM, Ayala AG. Primary adenocarcinoma of the urinary bladder. South Med J. 1972;65(5):527–30.
12. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358(1):36–46.
13. Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, et al. Capecitabine/cisplatin versus S-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009;20(4):666–73.
14. Barter ZE, Tucker GT, Rowland-Yeo K. Differences in cytochrome p450-mediated pharmacokinetics between Chinese and Caucasian populations predicted by mechanistic physiologically based pharmacokinetic modelling. Clin Pharmacokinet. 2013;52(12):1085–100.
15. Churillo MA. Genomic biomarkers related to drug response in Venezuelan populations. Drug Metabol Drug Interact. 2014; doi:10.1515/dmdi-2014-0019.
16. Zhang H, Jiang H, Wu Z, Fang Z, Fan J, Ding Q. Primary adenocarcinoma of the urinary bladder: a single site analysis of 21 cases. Int Urol Nephrol. 2013;45(1):107–11.
17. Siefer-Radtke A. Urachal carcinoma: surgical and chemotherapeutic options. Expert Rev Anticancer Ther. 2006;6(12):1715–21.

do:10.1186/1471-2490-15-3
Cite this article as: Yu et al. Neoadjuvant chemotherapy for primary adenocarcinomas of the urinary bladder: a single-site experience. BMC Urology. 2015;15:3.

Submit your next manuscript to BioMed Central and take full advantage of:

• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit